A new obesity approach targets fat storage pathways, without the usual trade-offs, hinting at longer and healthier lives.
Obesity drugs have worked like volume controls on appetite, where you turn it down and hope the body follows. What if the real issue isn’t how much we eat, but how efficiently our bodies hold on to what we eat? What if the problem isn’t hunger, but storage?
These are the questions driving Antag Therapeutics’ latest data, presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. At the core is AT7687, a first-in-class peptide designed not to suppress hunger, but to block a biological signal linked to fat storage [1]. A subtle pivot, but it could change everything – from “eat less” to “store less.”
Most people now recognize the names of GLP-1 drugs, treatments that help reduce appetite and slow digestion. They’ve reshaped the obesity conversation, but they’re not perfect. For some, the side effects are difficult. For others, the results plateau.
AT7687 takes a different route. Instead of telling the brain to eat less, it targets the GIP receptor, a pathway tied to how the body stores fat and manages insulin. Think of it this way: if metabolism were a household budget, most drugs try to cut spending. AT7687 is trying to fix the part where money keeps getting locked into the wrong accounts. By “switching off” this storage signal, the therapy aims to help the body use energy more efficiently, rather than simply limiting intake.
At ADA 2026, Antag presented data from its first-in-human study of AT7687, involving both healthy individuals and people living with obesity. The headline finding was measured but important: the drug was well tolerated and suitable for once-weekly subcutaneous injection.
For an early-stage biotech, safety is the first real milestone. Earlier results from January reinforce this, showing a “favorable safety and tolerability profile across all doses,” with no serious adverse events and no drug-related discontinuations [2].
Equally notable was the absence of significant gastrointestinal issues, often the trade-off with existing treatments. In fact, all GI-related effects were mild and similar to placebo.
Beyond safety, the drug showed early signs of influencing broader metabolic markers, including reductions in LDL cholesterol and resting heart rate. In other words, it may be doing more than just nudging weight; it could be quietly reshaping underlying health.
The real story: combinations
If AT7687 alone is promising, its role as a “team player” may be what makes things interesting. In a separate presentation, Antag shared preclinical data combining AT7687 with cagrilintide, a compound already known for its weight-lowering effects. The result: “robust weight loss and substantial improvements in insulin sensitivity and body composition” in obese, insulin-resistant primates.
Earlier data helps fill in the picture. The combination delivered weight loss in the low double-digit percentage range – outperforming either therapy alone – and, importantly, without the effect plateauing over time.
Even more intriguing: the additional weight loss wasn’t driven by eating less. Food intake remained similar to that of animals treated with cagrilintide alone. That suggests that the body isn’t just consuming fewer calories; it’s handling them differently.
The combination also led to preferential fat loss over lean mass and improved insulin sensitivity, two markers that matter far more for long-term health than the number on a scale.
“The potential for AT7687 to not only enhance weight loss, but also have strong additive effect on both healthier body composition and insulin sensitivity without increasing the tolerability burden, is especially compelling in this insulin-resistant study group,” said Jörg Möller, CEO of Antag Therapeutics.
A shift in obesity science
For decades, obesity treatment has oscillated between two ideas: eat less or move more. Modern drugs added a third: change the hormones that regulate hunger. What Antag is proposing feels like a fourth: change how the body stores and uses energy at a deeper level.
Obesity isn’t just about excess weight, but also about how that weight interacts with the body over time. Fat stored in the wrong places, insulin resistance and chronic inflammation are what ultimately drive disease and shorten healthspan. By targeting GIPR, AT7687 is stepping into that more complex terrain.
Longevity.Technology: The longevity field has been inching toward a realization: extending life is about adding years and reducing the slow, cumulative damage that builds up along the way. Obesity accelerates that damage. It strains the cardiovascular system, disrupts metabolic balance and increases the risk of age-related diseases. So a therapy that improves insulin sensitivity, supports healthier body composition and avoids the burden of harsh side effects isn’t just a weight loss drug; it’s a potential longevity tool.
Perhaps more importantly, it hints at a future where treatment is flexible. AT7687 is designed to work as both a standalone therapy and in combination with others, opening the door to more personalized approaches.
What comes next
AT7687 has completed Phase 1, with Phase 2a studies expected to begin in 2026. Antag has already secured $93.8 million (€80 million) in Series A funding, signaling strong investor confidence in this approach.
However, early promise is just that. The real test will come in larger, longer studies, where efficacy, durability and real-world tolerability are put under pressure. Still, the direction is hard to ignore because if the future of obesity treatment shifts from controlling appetite to reprogramming metabolism, we may be looking at a new way of understanding how the body holds on and how it finally learns to let go.
[1] https://antagtx.com/antag-therapeutics-to-present-data-on-at7687-its-first-in-class-gipr-antagonist-peptide-at-the-american-diabetes-associations-2026-scientific-sessions/
[2] https://antagtx.com/antag-therapeutics-demonstrates-compelling-potential-of-its-novel-gipr-antagonist-for-obesity-reporting-excellent-tolerability-in-phase-1-and-enhanced-weight-loss-in-amylin-combination-study/
